カテゴリー：
（ABC order）
ORTHOREBIRTH has entrusted CBC to exclusively distribute and sell ReBOSSIS in Europe. The sale is supposed to start smoothly after ReBOSSIS obtains CE Marking. CBC is a trading firm which operates its business in multiple fields. For example, CBC handles in chemical resins for industry use, electronic materials, medical products, health-promoting foods and so on.
ORTHOREBIRTH have entrusted Kyocera for the distribution and sales of ReBOSSIS-MK in the field of maxillofacial and plastic surgery in Japan in November 2022. Kyocera provides medical products such as artificial joints and dental implants developed with ceramic and metal material technology and surface treatment technology.
KMTI is a U.S. subsidiary of the Kyocera Group, which manufactures and sells medical devices in the United States. ORTHOREBIRTH entered into a business alliance agreement with KMTI in the fall of 2019 for the exclusive sales of ReBOSSIS andReBOSSIS QDS—now marketed as BIOCERA FIBERS and BIOCERA FIBERS QDS—across the U.S. market.
ORTHOREBIRTH have entrusted NAKASHIMA HEALTHFORCE for the distribution and sales of ReBOSSIS-J in the territory of Japan in February 2022. NAKASHIMA HEALTHFORCE develops,manufactures, and sells medical devices such as osteosynthesis materials and spinal fixation devices,mainly for artificial joints.
ORTHOREBIRTH have entrusted SHOFU for the distribution and sales of ReBOSSIS-MS in the field of maxillofacial and plastic surgery in Japan in November 2022. SHOFU develops, manufactures, and sells mainly dental materials and equipment.
ORTHOREBIRTH have entrusted TEIJIN MEDICAL TECHNOLOGY for the distribution and sales of ReBOSSIS-MT in the field of maxillofacial and plastic surgery in Japan in November 2022. TEIJIN MEDICAL TECHNOLOGY develops, manufactures, and sells medical devices mainly using bio-degradable and resorbable bone-jointing materials and proprietary polymer processing technologies.
